Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MDxHealth (MDXH) Convertible Debt (2021 - 2025)

Historic Convertible Debt for MDxHealth (MDXH) over the last 5 years, with Q2 2025 value amounting to $136.2 million.

  • MDxHealth's Convertible Debt rose 171.87% to $136.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $136.2 million, marking a year-over-year increase of 171.87%. This contributed to the annual value of $135.9 million for FY2024, which is 1694.14% up from last year.
  • As of Q2 2025, MDxHealth's Convertible Debt stood at $136.2 million, which was up 171.87% from $135.9 million recorded in Q4 2024.
  • In the past 5 years, MDxHealth's Convertible Debt ranged from a high of $136.2 million in Q2 2025 and a low of $25.4 million during Q4 2021
  • For the 5-year period, MDxHealth's Convertible Debt averaged around $98.9 million, with its median value being $113.8 million (2023).
  • Its Convertible Debt has fluctuated over the past 5 years, first soared by 31901.57% in 2023, then surged by 171.87% in 2025.
  • MDxHealth's Convertible Debt (Quarter) stood at $25.4 million in 2021, then surged by 316.05% to $105.8 million in 2022, then grew by 9.82% to $116.2 million in 2023, then increased by 16.94% to $135.9 million in 2024, then increased by 0.23% to $136.2 million in 2025.
  • Its Convertible Debt stands at $136.2 million for Q2 2025, versus $135.9 million for Q4 2024 and $133.9 million for Q2 2024.